Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2022-09-01 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
创业板上市公司股权激励计划自查表
Governance Information Classification · 95% confidence The document is a detailed compliance self-inspection checklist related to a stock incentive plan for a listed company, Anhui Anke Bioengineering (Group) Co., Ltd. It includes numerous compliance checks, legal and regulatory adherence, and internal governance related to the stock incentive plan. There is no indication that this is an announcement or a brief summary; rather, it is a regulatory compliance document focused on governance and management of stock incentives. It does not contain financial statements or earnings data, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement or a certification letter. The content is focused on governance and compliance of the stock incentive plan, which aligns best with Governance Information (CGR).
2022-09-01 Chinese
关于修订第三期限制性股票激励计划相关内容的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding revisions to the third phase of its restricted stock incentive plan. It details changes to the stock lock-up periods, performance assessment criteria, and conditions for lifting restrictions on stock. The content focuses on stock incentive plan adjustments, performance targets, and related governance matters. There is no financial statement data, earnings information, or audit content. The document is a formal announcement about management and board decisions related to stock incentives, which fits the category of Board/Management Information (MANG). The document length is over 11,000 characters, indicating it is not a brief notice or a report publication announcement. Therefore, the classification is MANG with high confidence.
2022-09-01 Chinese
第三期限制性股票激励计划（草案修订稿）摘要
Board/Management Information Classification · 95% confidence The document is a detailed plan regarding a third phase restricted stock incentive plan for Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It includes legal references, stock quantities, pricing, eligibility, vesting periods, performance conditions, and governance related to the stock incentive plan. The content is focused on the company's management and board-level decisions about stock incentives for executives and key employees. It is not a financial report, earnings release, or regulatory filing about financial results. It is not a proxy solicitation or voting results announcement. It is a management/board-related document about stock incentive plans, which falls under the category of Board/Management Information (MANG). The document length and detail confirm it is the plan itself, not just an announcement or summary, so it is not RPA or RNS. Therefore, the best classification is MANG with high confidence.
2022-09-01 Chinese
独立董事关于公司第七届董事会第二十三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters related to the company's third restricted stock incentive plan and its revised draft, including the assessment and approval process. It discusses compliance with relevant laws and regulations, the company's governance, and the submission of these matters to the shareholders' meeting for approval. The content focuses on governance and management opinions rather than financial results or audit findings. It is not a full annual report, audit report, or earnings release. It is not a simple announcement or certification but a detailed management/board opinion on governance and incentive plans. Therefore, the document fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to board or senior management matters, including incentive plans and governance.
2022-09-01 Chinese
关于独立董事公开征集委托投票权的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by an independent director publicly soliciting proxy voting rights for a specific upcoming shareholders' meeting (the 2022 second extraordinary general meeting). It details the legal basis, procedures, and instructions for shareholders to delegate their voting rights to the independent director. It includes an authorization proxy form for shareholders to fill out and submit. The content focuses on the solicitation of voting rights and proxy arrangements rather than the results of voting or the meeting itself. It is not a report of voting results (DVA), nor is it a notice of the meeting itself (PSI). It is a solicitation related to proxy voting rights, which is a specific type of announcement. Given the nature of the document, it best fits the category of Regulatory Filings (RNS) as it is a regulatory announcement related to proxy solicitation but does not fit the Proxy Solicitation & Information Statement (PSI) category which typically includes materials sent to shareholders to request votes, not a public solicitation by an independent director. The document is about the solicitation of proxy votes by an independent director, which is a regulatory announcement.
2022-09-01 Chinese
关于第七届监事会第二十次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 20th meeting of the 7th Supervisory Board of Anhui Anke Biotechnology (Group) Co., Ltd. It details voting results on proposals related to the company's third restricted stock incentive plan and its implementation assessment management measures. The document includes voting outcomes and mentions that these proposals will be submitted to the shareholders' meeting for approval. The content focuses on board/management decisions and internal governance matters rather than financial results, audit, or regulatory filings. It is not a full report but an announcement of board-level decisions. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report. It is not a voting result declaration (DVA) because it reports supervisory board meeting resolutions, not shareholder meeting voting results.
2022-09-01 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.